<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="EN" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Clin Pharmacol</journal-id><journal-id journal-id-type="pmc-domain-id">279</journal-id><journal-id journal-id-type="pmc-domain">brjclinpharm</journal-id><journal-id journal-id-type="publisher-id">bcp</journal-id><journal-title-group><journal-title>British Journal of Clinical Pharmacology</journal-title></journal-title-group><issn pub-type="ppub">0306-5251</issn><issn pub-type="epub">1365-2125</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC2015017</article-id><article-id pub-id-type="pmcid-ver">PMC2015017.1</article-id><article-id pub-id-type="pmcaid">2015017</article-id><article-id pub-id-type="pmcaiid">2015017</article-id><article-id pub-id-type="pmid">11136293</article-id><article-id pub-id-type="doi">10.1046/j.1365-2125.2000.00297.x</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Population Pharmacokinetics</subject></subj-group></article-categories><title-group><article-title>Population PK and PK/PD modelling of microencapsulated octreotide acetate in healthy subjects</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Zhou</surname><given-names initials="H">Honghui</given-names></name><xref ref-type="aff" rid="au1">1</xref><xref ref-type="author-notes" rid="fn2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="TL">Tian-Ling</given-names></name><xref ref-type="aff" rid="au1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Marino</surname><given-names initials="M">Mark</given-names></name><xref ref-type="aff" rid="au1">1</xref><xref ref-type="author-notes" rid="fn3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lau</surname><given-names initials="H">Henry</given-names></name><xref ref-type="aff" rid="au1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Miller</surname><given-names initials="T">Thomas</given-names></name><xref ref-type="aff" rid="au1">1</xref><xref ref-type="author-notes" rid="fn4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kalafsky</surname><given-names initials="G">Gaetana</given-names></name><xref ref-type="aff" rid="au1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>McLeod</surname><given-names initials="JF">James F</given-names></name><xref ref-type="aff" rid="au1">1</xref></contrib><aff id="au1"><institution>From the Department of Clinical Pharmacology, Novartis Pharmaceuticals Corporation</institution><addr-line>East Hanover, NJ, USA</addr-line></aff></contrib-group><author-notes><corresp id="cor1"><italic>Correspondence:</italic> James F. McLeod, MD, Novartis Pharmaceuticals Corporation, 59 Route, 10, East Hanover, NJ 07936, USA. Tel.:+1 (973) 781&#8211;5999.</corresp><fn id="fn2"><label>2</label><p>Current addresses: Janssen Research Foundation, Titusville, NJ.</p></fn><fn id="fn3"><label>3</label><p>Schering-Plough Research Institute, Kenilworth, NJ</p></fn><fn id="fn4"><label>4</label><p>Knoll Pharmaceuticals Co., Parsippany, NJ, USA.</p></fn></author-notes><pub-date pub-type="ppub"><month>12</month><year>2000</year></pub-date><volume>50</volume><issue>6</issue><issue-id pub-id-type="pmc-issue-id">151583</issue-id><fpage>543</fpage><lpage>552</lpage><history><date date-type="received"><day>13</day><month>1</month><year>2000</year></date><date date-type="accepted"><day>04</day><month>9</month><year>2000</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>06</month><year>2001</year></date></event><event event-type="pmc-live"><date><day>14</day><month>01</month><year>2008</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2010-12-24 12:38:08.153"><day>24</day><month>12</month><year>2010</year></date></event></pub-history><permissions><copyright-statement>&#169; 2000 Blackwell Science Ltd</copyright-statement><copyright-year>2000</copyright-year></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="bcp0050-0543.pdf"/><abstract><sec><title>Aims</title><p>To develop a population model that can describe the pharmacokinetic profile of microencapsulated octreotide acetate in healthy cholecystectomized subjects. To investigate the correlation between serum IGF-1 and octreotide concentration.</p></sec><sec sec-type="methods"><title>Methods</title><p>A population pharmacokinetic analysis was performed on octreotide data obtained following a single dose of 30 mg microencapsulated octreotide acetate intramuscularly. The relationship between serum IGF-1 concentration and octreotide concentration was effectively described by a population pharmacokinetic/pharmaco-dynamic model.</p></sec><sec><title>Results</title><p>The pharmacokinetic profile of octreotide was characterized by an initial peak of octreotide followed by a sustained-release of drug. Plateau concentration were sustained up to day 70, and gradually declined to below the detection limit by day 112. A one-compartment linear model was constructed which consisted of two absorption processes, characterized by <italic>K</italic><sub>IR</sub> and <italic>K</italic><sub>SR</sub>, rate constants for immediate-release and sustained-release, respectively, with first-order elimination (<italic>K</italic><sub>e</sub>; 1.05 h<sup>&#8722;1</sup>). The surface, unencapsulated drug was immediately absorbed into the central compartment with first-order absorption (<italic>K</italic><sub>IR</sub> 0.0312 h<sup>&#8722;1</sup>), while the microencapsulated drug was first released in a zero-order fashion into a depot before being absorbed into the central compartment with first-order absorption (<italic>K</italic><sub>SR</sub>; 0.00469 h<sup>&#8722;1</sup>) during a period of &#964; (1680 h). Body weight and gender were important covariates for the apparent volume of distribution. The type of formulation was an important covariate for <italic>K</italic><sub>IR</sub> but had no effect on <italic>K</italic><sub>SR</sub>. An inhibitory E<sub>max</sub> population pharmacokinetic/pharmacodynamic model could adequately describe the relationship between IGF-1 (expressed as percent baseline) and octreotide concentration. Baseline IGF-1 concentration was found to be a significant covariate for the baseline effect (E<sub>0</sub>). A relationship between GH concentration and octreotide concentration was not established.</p></sec><sec><title>Conclusions</title><p>The pharmacokinetic profile of microencapsulated octreotide acetate was effectively described by the derived population model. The relationship between IGF-1 and drug concentration could be used to guide optimization of therapeutic octreotide dosage regimens.</p></sec></abstract><kwd-group><kwd>cholecystectomized</kwd><kwd>IGF-1</kwd><kwd>microencapsulated octreotide acetate</kwd><kwd>population PK/ PD</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>